Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases
- 16 February 2021
- journal article
- review article
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (3) , e14883
Abstract
Ustekinumab (STELARA®), a human monoclonal antibody directed against IL‐12 and IL‐23, is FDA‐approved to treat psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Increasing recognition of paradoxical skin reactions induced by older biologic therapies used for inflammatory bowel diseases (IBD), such as adalimumab and infliximab, has led to the investigation of ustekinumab for the treatment of the cutaneous and gastrointestinal manifestations of IBD. In addition, ustekinumab may show efficacy in treating paradoxical cutaneous reactions to tumor necrosis factor‐alpha (TNF‐α) inhibitors. A search of the Medline/PubMed database, with additional citations obtained from the references section of relevant articles, yielded 22 articles that were included in this review. Ustekinumab is a safe and effective option for treating the cutaneous manifestations of IBD, such as metastatic Crohn's disease and pyoderma gangrenosum. It is also an effective treatment for TNF‐α inhibitor‐induced paradoxical skin reactions such as psoriasis that do not remit spontaneously or with conventional treatment. Additional studies should focus on the optimal dosing of ustekinumab for dermatologic conditions beyond psoriasis.Keywords
This publication has 42 references indexed in Scilit:
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut, 2013
- Malignant melanoma during ustekinumab therapy of Crohnʼs diseaseInflammatory Bowel Diseases, 2012
- Discovery and mechanism of ustekinumabmAbs, 2011
- Treatment of Refractory Tumor Necrosis Factor Inhibitor –Induced Palmoplantar Pustulosis: A Report of 2 CasesArchives of Dermatology, 2011
- IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12International Immunology, 2008
- Significance of Erythema Nodosum and Pyoderma Gangrenosum in Inflammatory Bowel DiseasesMedicine, 2008
- Interleukin-12, interleukin-23, and psoriasis: Current prospectsJournal of the American Academy of Dermatology, 2007
- A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease GeneScience, 2006
- Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cellsNature, 1996
- THE EXTRA-INTESTINAL COMPLICATIONS OF CROHNʼS DISEASE AND ULCERATIVE COLITIS: A STUDY OF 700 PATIENTSMedicine, 1976